Published in Thromb Haemost on April 01, 2009
TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. Cell Signal (2012) 1.82
Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem (2010) 1.41
TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res (2011) 1.37
Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol (2010) 1.10
Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res (2011) 1.04
Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta (2011) 1.01
Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis. J Biol Chem (2013) 0.99
Pathogenesis of Systemic Sclerosis. Front Immunol (2015) 0.89
Inhibition of lysosomal protease cathepsin D reduces renal fibrosis in murine chronic kidney disease. Sci Rep (2016) 0.85
Antifibrotic effects of KS370G, a caffeamide derivative, in renal ischemia-reperfusion injured mice and renal tubular epithelial cells. Sci Rep (2014) 0.81
Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta (2014) 0.80
An in vitro model for the pro-fibrotic effects of retinoids: mechanisms of action. Br J Pharmacol (2013) 0.79
α2AP mediated myofibroblast formation and the development of renal fibrosis in unilateral ureteral obstruction. Sci Rep (2014) 0.79
uPARAP function in cutaneous wound repair. PLoS One (2014) 0.78
Ureteral Obstruction-Induced Renal Fibrosis: An In Vivo Platform for Mechanistic Discovery and Therapeutic Intervention. Cell Dev Biol (2012) 0.75
The Tubulointerstitial Pathophysiology of Progressive Kidney Disease. Adv Chronic Kidney Dis (2017) 0.75
Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway. Kidney Int (2016) 0.75
Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98
Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol (2004) 5.43
LRP: a multifunctional scavenger and signaling receptor. J Clin Invest (2001) 5.31
Macrophage diversity in renal injury and repair. J Clin Invest (2008) 4.41
Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol (2005) 4.35
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol (1990) 3.81
The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32
Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int (2007) 3.09
Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem (1994) 2.92
PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int (2001) 2.41
Progression in chronic kidney disease. Adv Chronic Kidney Dis (2005) 2.18
Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy. J Clin Invest (2002) 2.15
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A (2002) 2.14
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem (1995) 2.06
Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis (2008) 2.01
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost (2005) 1.96
Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol (2005) 1.94
uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost (2007) 1.86
Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol (2003) 1.83
Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol (2006) 1.82
Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. J Am Soc Nephrol (2007) 1.81
Phagocytosis and intracellular digestion of collagen, its role in turnover and remodelling. Histochem J (1996) 1.77
Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice. Kidney Int (2005) 1.74
Endogenous urokinase lacks antifibrotic activity during progressive renal injury. Am J Physiol Renal Physiol (2007) 1.68
The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem (2004) 1.64
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol (2004) 1.64
Bradykinin decreases plasminogen activator inhibitor-1 expression and facilitates matrix degradation in the renal tubulointerstitium under angiotensin-converting enzyme blockade. J Am Soc Nephrol (2004) 1.61
uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol (2003) 1.60
Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl (2004) 1.58
Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol (2008) 1.52
Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest (2002) 1.45
Identification and characterization of the endocytic transmembrane glycoprotein Endo180 as a novel collagen receptor. Mol Biol Cell (2003) 1.44
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis. J Clin Invest (2003) 1.42
Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol (2005) 1.40
Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol (1994) 1.37
Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling. J Clin Invest (2007) 1.33
A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake. EMBO Rep (2003) 1.31
Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy. J Am Soc Nephrol (2003) 1.31
Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol (2007) 1.25
Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J Clin Invest (1997) 1.24
A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol (2008) 1.24
Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol (2002) 1.24
uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp Cell Res (2004) 1.23
Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood (2000) 1.22
The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem (2002) 1.21
Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol (2007) 1.21
CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD. J Am Soc Nephrol (2009) 1.15
The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem (2002) 1.14
Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost (2004) 1.07
Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci STKE (2003) 1.06
Pathways to recovery and loss of nephrons in anti-Thy-1 nephritis. J Am Soc Nephrol (2003) 1.06
tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J Am Soc Nephrol (2008) 1.04
High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler Thromb Vasc Biol (2006) 1.02
Can renal fibrosis be reversed? Pediatr Nephrol (2005) 1.02
Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ Res (2004) 1.01
In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest (2002) 1.01
Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. J Am Soc Nephrol (2003) 1.01
Glomerulosclerosis in aging humans is not influenced by gender. Am J Kidney Dis (1999) 0.99
The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost (2004) 0.97
The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. Kidney Int (2006) 0.94
Human plasma fibronectin as a substrate for human urokinase. Biochem J (1989) 0.94
Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a pro-inflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci (2005) 0.94
Urokinase and its receptors in chronic kidney disease. Front Biosci (2008) 0.94
Solution structure of recombinant somatomedin B domain from vitronectin produced in Pichia pastoris. Protein Sci (2007) 0.91
Clustering of urokinase receptors (uPAR; CD87) induces proinflammatory signaling in human polymorphonuclear neutrophils. J Immunol (2000) 0.91
The urokinase receptor and the regulation of cell proliferation. Thromb Haemost (2005) 0.90
Plasminogen and wound healing. Nat Med (1996) 0.90
A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma. J Clin Invest (1999) 0.90
Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost (2001) 0.87
The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung. J Immunol (2005) 0.87
Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein. J Am Soc Nephrol (2004) 0.85
Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1. Thromb Haemost (2000) 0.81
Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int (2001) 0.81
Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils. J Immunol (2001) 0.81
Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis. J Am Soc Nephrol (2008) 0.80
Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. Biol Chem (2003) 0.80
Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells. Blood (2008) 0.79
Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant (2005) 0.78
Protease nexin 1 in the murine kidney: glomerular localization and up-regulation in glomerulopathies. Kidney Int (1996) 0.78
A novel, specific pro-urokinase complex on monocyte-like cells, detected by transglutaminase-catalyzed cross-linking. FEBS Lett (1993) 0.77
Rationale for combining blockers of the renin-angiotensin system. Semin Nephrol (2007) 0.76